| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 550-850 was used as the immunogen for the recombinant CFTR antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Recombinant CFTR Antibody / Cystic Fibrosis Transmembrane Regulator is an antibody targeting CFTR. Host: Mouse. Monoclonal. Clone: rCFTR/7175. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: CFTR.
- Immunogen: A portion of amino acids 550-850 was used as the immunogen for the recombinant CFTR antibody..
- Species reactivity: Human.
- Localization: Cell surface, Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
Recognizes a protein of 165-170kDa, identified as cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is composed of two membrane-spanning domains (MSD), two nucleotide-binding domains (NBD), and an R domain.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
